Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: August 3, 2022
Purpose: Regulation FD Disclosure to furnish investor presentations and Q2 2022 earnings supplemental materials to institutional investors and analysts.
Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached Exhibits 99.1 and 99.2, which are not included in the source text.
Material Changes
No material financial changes or operational updates are detailed in the text of this 8-K. The filing serves solely to distribute updated investor presentations and supplemental materials, which replace all prior investor presentations filed by the Company.
Guidance, Outlook, and Risks
Management Commentary: The Company notes that the information provided in the attached presentations may be amended or updated at any time through future filings.
Legal Disclaimer: The information in Item 7.01 and the attached exhibits is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Availability: Presentations are available on the Company's website, though the Company reserves the right to discontinue availability at any time.
Key Facts for Investor Verification
- Verify the specific financial figures and operational updates in the attached Exhibits 99.1 (Corporate Presentation) and 99.2 (Q2 2022 Earnings Supplemental Materials), as they are not present in the 8-K text.
- Confirm that this filing supersedes all prior investor presentations.
- Note that the Company is an emerging growth company.
- Check the Company website (www.aquestive.com) for the availability of the referenced materials, subject to potential discontinuation.